| |
Cryptogenic HCC (n = 35)
|
HBV-HCC
|
* p
|
HCV-HCC
|
**p
|
ALC-HCC
|
***p
|
|---|
| | |
(n = 321)
| |
(n = 69)
| |
(n = 55)
| |
|---|
|
Age, yr†
|
68.3 ± 10.5
|
57.1 ± 10.3
|
<0.001
|
68.1 ± 9.0
|
0.896
|
65.5 ± 10.0
|
0.164
|
|
Gender, Male††
|
20 (57.1)
|
244 (76.0)
|
0.015
|
44 (63.8)
|
0.512
|
51 (92.7)
|
<0.001
|
|
BMI (kg/m2) †
|
24.6 ± 3.3
|
23.4 ± 3.4
|
0.034
|
22.2 ± 3.9
|
0.002
|
24.0 ± 4.3
|
0.143
|
|
Obesity††
|
16 (45.7)
|
85 (26.7)
|
0.018
|
13 (18.8)
|
0.004
|
12 (21.8)
|
0.017
|
|
Diabetes ††
|
13 (37.1)
|
55 (17.1)
|
0.004
|
17 (24.6)
|
0.183
|
19 (34.5)
|
0.802
|
|
Hypertension ††
|
20 (57.1)
|
77 (24.0)
|
<0.001
|
32 (46.4)
|
0.299
|
18 (32.7)
|
0.022
|
|
Hyperlipidemia††
|
9 (25.7)
|
10 (3.1)
|
<0.001
|
4 (5.8)
|
0.004
|
2 (3.6)
|
0.003
|
|
Follow-up period, mo†
|
26.1 ± 27.8
|
28.5 ± 27.0
|
0.573
|
29.9 ± 25.1
|
0.362
|
29.2 ± 25.6
|
0.518
|
|
Albumin (g/dL) †
|
3.7 ± 0.5
|
3.8 ± 0.6
|
0.346
|
3.7 ± 0.6
|
0.780
|
3.7 ± 0.5
|
0.545
|
|
Bilirubin (mg/dL) †
|
1.2 ± 0.7
|
1.6 ± 2.4
|
0.437
|
1.8 ± 2.7
|
0.551
|
1.6 ± 1.9
|
0.216
|
|
ALP (IU/L) †
|
123.3 ± 73.3
|
137.2 ± 97.2
|
0.555
|
125.2 ± 63.1
|
0.728
|
132.6 ± 91.8
|
0.855
|
|
AST (IU/L) †
|
83.8 ± 165.4
|
89.3 ± 140.5
|
0.342
|
111.9 ± 114.6
|
<0.001
|
53.2 ± 31.9
|
0.419
|
|
ALT (IU/L) †
|
58.7 ± 99.0
|
64.4 ± 98.4
|
0.111
|
78.6 ± 60.6
|
0.001
|
47.4 ± 72.7
|
0.371
|
|
Platelet (103/μL) †† (<10/10 ~ 13/>13)
|
5/7/23
|
87/50/182
|
0.157
|
19/18/32
|
0.056
|
14/9/42
|
0.263
|
|
PT-INR†
|
1.14 ± 0.16
|
1.15 ± 0.18
|
0.897
|
1.15 ± 0.14
|
0.791
|
1.14 ± 0.19
|
0.593
|
|
Hemoglobin (g/dL) †
|
12.6 ± 2.3
|
13.6 ± 2.0
|
0.007
|
12.8 ± 2.1
|
0.570
|
13.1 ± 2.2
|
0.460
|
|
Na (mmol/L) †
|
137.0 ± 8.8
|
137.4 ± 9.6
|
0.551
|
137.7 ± 4.0
|
0.535
|
137.9 ± 3.4
|
0.340
|
|
Creatinine (mg/dL) †
|
0.9 ± 0.2
|
1.0 ± 0.3
|
0.738
|
1.2 ± 1.0
|
0.040
|
1.2 ± 1.0
|
0.537
|
|
C-P class (A/BC) ††
|
29/6
|
246/75
|
0.404
|
50/19
|
0.241
|
40/15
|
0.268
|
|
MELD score†
|
9.0 ± 2.9
|
9.6 ± 3.2
|
0.273
|
10.2 ± 3.7
|
0.076
|
10.5 ± 4.3
|
0.051
|
- †Expressed as the mean ± standard deviation. ††Expressed as the number of subjects (%).
- Values in bold, statistically significant (p < 0.05).
-
BMI, Body mass index; AST, Aspartate transaminase; ALT, Alanine transaminase; PT-INR, Prothrombin time-international normalized ratio; C-P class, Child-Pugh class; MELD, Model for end-stage liver disease; HBV-HCC, Hepatitis B-associated hepatocellular carcinoma; HCV-HCC, Hepatitis C-associated hepatocellular carcinoma; ALC-HCC, Alcohol-associated hepatocellular carcinoma.
- *p: Cryptogenic HCC vs. HBV-HCC.
- **p: Cryptogenic HCC vs. HCV-HCC.
- ***p: Cryptogenic HCC vs. ALC-HCC.
